Hyphens Pharma nearly doubles 1QFY2024 earnings

1
Comment
Favorite

Hyphens Pharma nearly doubles 1QFY2024 earnings

The Edge Singapore05-14

Revenue increased by 44.4% Hyphens Pharma International has reported 97.6% higher y-o-y earnings of $2.7 million for 1QFY2024, nearly double that of the year-earlier period. Revenue in the same three ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2435788695?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-14 10:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2435788695","market":"us","top_or_hot":-1,"title":"Hyphens Pharma nearly doubles 1QFY2024 earnings","media":"The Edge Singapore","content":"<div>\n<p>Revenue increased by 44.4% Hyphens Pharma International has reported 97.6% higher y-o-y earnings of $2.7 million for 1QFY2024, nearly double that of the year-earlier period.\nRevenue in the same three ...</p>\n\n<a href=\"https://www.theedgesingapore.com/capital/results/hyphens-pharma-nearly-doubles-1qfy2024-earnings?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS\">Source Link</a>\n\n</div>\n","source":"edge_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hyphens Pharma nearly doubles 1QFY2024 earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHyphens Pharma nearly doubles 1QFY2024 earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-14 10:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.theedgesingapore.com/capital/results/hyphens-pharma-nearly-doubles-1qfy2024-earnings?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS><strong>The Edge Singapore</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Revenue increased by 44.4% Hyphens Pharma International has reported 97.6% higher y-o-y earnings of $2.7 million for 1QFY2024, nearly double that of the year-earlier period.\nRevenue in the same three ...</p>\n\n<a href=\"https://www.theedgesingapore.com/capital/results/hyphens-pharma-nearly-doubles-1qfy2024-earnings?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"1J5.SI","symbol_name":"凯帆药剂国际有限公司","start_time":0,"source_url":"https://www.theedgesingapore.com/capital/results/hyphens-pharma-nearly-doubles-1qfy2024-earnings?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","article_id":"2435788695","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2435788695","pubTimestamp":1715653146,"sourceInfo":{"source_id":"edge_highlight","name":"Edge"},"weMediaInfo":null,"summary":"Revenue increased by 44.4% ","collect":0,"end_time":0,"defaultTopTitle":"theedgesingapore.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"1J5.SI":"凯帆药剂国际有限公司"},"translate_title":"Hyphens Pharma 2024财年第一季度收益几乎翻一番","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"1J5.SI":1},"content_text":"Revenue increased by 44.4% Hyphens Pharma International has reported 97.6% higher y-o-y earnings of $2.7 million for 1QFY2024, nearly double that of the year-earlier period.\nRevenue in the same three months ended March increased by 44.4% to $48 million.\nThe company attributes the better numbers to all-around improvement in sales of its products, especially that from its so-called speciality pharma principals segment, which has rebounded from supply chain woes in 1HFY2023.\nIn addition, the introduction of new products from the likes of Laboratoires Gilbert in this segment helped drive sales too, the company adds.\nHyphens Pharma sells its proprietary products as well. The slight revenue dip for this segment was attributed to its channel partners stocking up in the preceding 4QFY2023.\nBesides boosting sales, the company plans to build long-term growth with acquisitions.\nHyphens Pharma shares closed at 27 cents on May 14, down 1.85% for the day and down 5.36% year to date.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}